How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and underlying liver function. In intermediate stage HCC, a high rate of recurrence and unsatisfactory treatment outcome after transarterial chemoembolization (TACE) are usually due to a large size and high number of tumors. TACE using drug-eluting beads has an advantage of a higher concentration of chemotherapeutic agent in the tumor. It might be applied to the patients with advanced diseases such as bilobar or recurrent HCC, and poor liver function. Blocking angiogenic stimuli after TACE would be a rational approach and radioembolization with 90Y is a novel interventional modality for intermediate stage HCC. The modest anti-cancer effect of sorafenib coupled with an adverse event is a hurdle to overcome in advanced HCC. External radiotherapy has achieved promising results in HCC with portal vein invasion. The role of internal radiation therapy with 90Y is not yet clear in advanced HCC. The safety and efficacy of hepatic arterial infusion chemotherapy have been reported in several studies. However, as in external radiotherapy, a well-designed randomized result is lacking. An appropriate combination strategy based on baseline patient and tumor characteristics may increase the survival of patients with intermediate or advanced HCC.

Original languageEnglish
Pages (from-to)598-602
Number of pages5
JournalDigestive Diseases
Volume30
Issue number6
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Neoplasms
Liver
Portal Vein
Safety
Recurrence
Drug Therapy
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{f6b7d149b99b4f779114ab7d9679ba86,
title = "How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage",
abstract = "Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and underlying liver function. In intermediate stage HCC, a high rate of recurrence and unsatisfactory treatment outcome after transarterial chemoembolization (TACE) are usually due to a large size and high number of tumors. TACE using drug-eluting beads has an advantage of a higher concentration of chemotherapeutic agent in the tumor. It might be applied to the patients with advanced diseases such as bilobar or recurrent HCC, and poor liver function. Blocking angiogenic stimuli after TACE would be a rational approach and radioembolization with 90Y is a novel interventional modality for intermediate stage HCC. The modest anti-cancer effect of sorafenib coupled with an adverse event is a hurdle to overcome in advanced HCC. External radiotherapy has achieved promising results in HCC with portal vein invasion. The role of internal radiation therapy with 90Y is not yet clear in advanced HCC. The safety and efficacy of hepatic arterial infusion chemotherapy have been reported in several studies. However, as in external radiotherapy, a well-designed randomized result is lacking. An appropriate combination strategy based on baseline patient and tumor characteristics may increase the survival of patients with intermediate or advanced HCC.",
author = "Kim, {Do Young} and Han, {Kwang Hyub}",
year = "2012",
month = "12",
day = "1",
doi = "10.1159/000343088",
language = "English",
volume = "30",
pages = "598--602",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",
number = "6",

}

How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. / Kim, Do Young; Han, Kwang Hyub.

In: Digestive Diseases, Vol. 30, No. 6, 01.12.2012, p. 598-602.

Research output: Contribution to journalArticle

TY - JOUR

T1 - How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage

AU - Kim, Do Young

AU - Han, Kwang Hyub

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and underlying liver function. In intermediate stage HCC, a high rate of recurrence and unsatisfactory treatment outcome after transarterial chemoembolization (TACE) are usually due to a large size and high number of tumors. TACE using drug-eluting beads has an advantage of a higher concentration of chemotherapeutic agent in the tumor. It might be applied to the patients with advanced diseases such as bilobar or recurrent HCC, and poor liver function. Blocking angiogenic stimuli after TACE would be a rational approach and radioembolization with 90Y is a novel interventional modality for intermediate stage HCC. The modest anti-cancer effect of sorafenib coupled with an adverse event is a hurdle to overcome in advanced HCC. External radiotherapy has achieved promising results in HCC with portal vein invasion. The role of internal radiation therapy with 90Y is not yet clear in advanced HCC. The safety and efficacy of hepatic arterial infusion chemotherapy have been reported in several studies. However, as in external radiotherapy, a well-designed randomized result is lacking. An appropriate combination strategy based on baseline patient and tumor characteristics may increase the survival of patients with intermediate or advanced HCC.

AB - Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and underlying liver function. In intermediate stage HCC, a high rate of recurrence and unsatisfactory treatment outcome after transarterial chemoembolization (TACE) are usually due to a large size and high number of tumors. TACE using drug-eluting beads has an advantage of a higher concentration of chemotherapeutic agent in the tumor. It might be applied to the patients with advanced diseases such as bilobar or recurrent HCC, and poor liver function. Blocking angiogenic stimuli after TACE would be a rational approach and radioembolization with 90Y is a novel interventional modality for intermediate stage HCC. The modest anti-cancer effect of sorafenib coupled with an adverse event is a hurdle to overcome in advanced HCC. External radiotherapy has achieved promising results in HCC with portal vein invasion. The role of internal radiation therapy with 90Y is not yet clear in advanced HCC. The safety and efficacy of hepatic arterial infusion chemotherapy have been reported in several studies. However, as in external radiotherapy, a well-designed randomized result is lacking. An appropriate combination strategy based on baseline patient and tumor characteristics may increase the survival of patients with intermediate or advanced HCC.

UR - http://www.scopus.com/inward/record.url?scp=84871830149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871830149&partnerID=8YFLogxK

U2 - 10.1159/000343088

DO - 10.1159/000343088

M3 - Article

C2 - 23258101

AN - SCOPUS:84871830149

VL - 30

SP - 598

EP - 602

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 6

ER -